Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm study of REGN-EB3 for Ebola virus disease (REGN-EVD)
jRCTs031220565Completed
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of REGN-EB3 in Ebola virus disease (EVD), sponsored by Japan Agency for Medical Research and Development. Primary endpoint: Mortality at 28 days. Started Jun 2023; status: completed.
02
Drugs
REGN-EB3
03
Conditions
Ebola virus disease (EVD)
Beyond the preview
Go deeper on jRCTs031220565.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031220565.